Mostrar el registro sencillo del ítem

dc.contributor.authorDrosten, Matthias 
dc.contributor.authorBarbacid, Mariano 
dc.date.accessioned2022-07-13T09:12:47Z
dc.date.available2022-07-13T09:12:47Z
dc.date.issued2022-05-16
dc.identifier.citationMol Oncol. 2022;16(5):1057-1071.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14702
dc.description.abstractFor decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12C inhibitors represents a landmark after 40 years of intense research efforts since the identification of KRAS as a human oncogene. Here, we discuss the mechanisms responsible for the rapid development of resistance to these inhibitors, as well as potential strategies to overcome this limitation. Other therapeutic strategies aimed at inhibiting KRAS oncogenic signaling by targeting either upstream activators or downstream effectors are also reviewed. Finally, we discuss the effect of targeting the mitogen-activated protein kinase (MAPK) pathway, both based on the failure of MEK and ERK inhibitors in clinical trials, as well as on the recent identification of RAF1 as a potential target due to its MAPK-independent activity. These new developments, taken together, are likely to open new avenues to effectively treat KRAS mutant LUAD.es_ES
dc.description.sponsorshipThis work was supported by grants from the European Research Council (ERC-2015-AdG/695566, THERACAN), the Spanish Ministry of Science, Innovation and Universities (RTC-2017-6576, RTI2018-094664-BI00) the Autonomous Community of Madrid (B2017/BMD-3884 iLUNG-CM) and the CRIS Cancer Foundation (to MB) as well as the Spanish Ministry of Science and Innovation (PID2020-116705RB-100) (to MD). MB is a recipient of an Endowed Chair from the AXA Research Fund.es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectgenetically engineered mouse tumor modelses_ES
dc.subjectKRAS(G12C) inhibitorses_ES
dc.subjectlung adenocarcinomaes_ES
dc.subjectRAF1es_ES
dc.subjectRAS signalinges_ES
dc.subjecttumor resistancees_ES
dc.subject.meshAdenocarcinoma of Lung es_ES
dc.subject.meshLung Neoplasms es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMutation es_ES
dc.subject.meshOncogenes es_ES
dc.subject.meshProtein Kinase Inhibitors es_ES
dc.subject.meshProto-Oncogene Proteins p21(ras) es_ES
dc.titleTargeting KRAS mutant lung cancer: light at the end of the tunnel.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID34951114es_ES
dc.format.volume16es_ES
dc.format.number5es_ES
dc.format.page1057-1071es_ES
dc.identifier.doi10.1002/1878-0261.13168es_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) es_ES
dc.contributor.funderGovernment of Spain es_ES
dc.contributor.funderUnión Europea. Comisión Europea es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderCRIS contra el Cáncer es_ES
dc.contributor.funderFundación AXA es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1878-0261es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/1878-0261.13168es_ES
dc.identifier.journalMolecular oncologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimentales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/695566/EUes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RTC-2017-6576es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RTI2018-094664-BI00es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/B2017/BMD-3884 iLUNG-CMes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PID2020-116705RB-100es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional